Walleye Capital LLC Akero Therapeutics, Inc. Call Options Transaction History

Walleye Capital LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $73,240 - $98,480	-4,000 Reduced 55.56%	3,200 $75,000
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $166,944 - $293,092	-9,400 Reduced 56.63%	7,200 $181,000
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $188,908 - $835,478	16,600 New	16,600 $387,000
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $612,374 - $944,208	16,600 New	16,600 $775,000
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $334,400 - $548,000	10,000 New	10,000 $548,000

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.15B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.